GSK
NEWS
Vectura Group plc confirms its R&D investment priorities, announces a proposed £50 million capital return and provides an unaudited pre-close trading update.
It’s no secret that artificial intelligence and machine learning play key roles in drug development. This week, multiple companies have advanced their AI programming.
According to reports, Novartis veteran Jonathan Symonds is likely to be named the next chairman of the board.
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
The two-drug combination of Dovato provided similar long-term viral suppression to common three-drug regimens.
Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers.
MorphoSys AG announced that its licensing partner GSK reported in a press release earlier the start of a phase 3 clinical development program with otilimab in rheumatoid arthritis.
Former founding managing director of JDRF T1D Fund joins DDF leadership team
Despite Political Rhetoric, Some Drug Prices Jumped on July 1, Including Medicines on Shortage Lists
The beginning of July is when many companies increase the price on prescription medications in the U.S. This year’s price increases are higher than the same period last year.
JOBS
IN THE PRESS